Overview of hyperuricaemia and gout

Current Pharmaceutical Design

Volumn 11, Issue 32, 2005, Pages 4117-4124

  Masseoud, D ^a   Rott, Keith ^a   Liu Bryan, R ^a   Agudelo, C ^a  

^a EMORY CLINIC   (United States)

Author keywords

Gout; Hyperuricaemia; Uricase; Xanthine oxidase inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIINFLAMMATORY AGENT; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIDANOSINE; ETHAMBUTOL; ETODOLAC; ETORICOXIB; FLURBIPROFEN; INDOMETACIN; LOOP DIURETIC AGENT; MECLOFENAMIC ACID; METHYLPREDNISOLONE ACETATE; NAPROXEN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PREDNISONE; PROBENECID; PYRAZINAMIDE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; URATE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ABDOMINAL PAIN; ACUTE DISEASE; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ARTHRITIS; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CATALYSIS; CATARACT; CLINICAL TRIAL; COGNITIVE DEFECT; DEGRADATION; DIABETES MELLITUS; DIAGNOSTIC TEST; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; EDEMA; EXFOLIATIVE DERMATITIS; FEVER; FLUID RETENTION; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GOUT; HEADACHE; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERURICEMIA; INCREASED APPETITE; INDIGESTION; INFECTION; INFLAMMATORY DISEASE; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER TOXICITY; LONG TERM CARE; MAMMAL; MULTIPLE ORGAN FAILURE; MYOPATHY; NAUSEA; NERVOUSNESS; NEUROPATHY; NONHUMAN; PANCYTOPENIA; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN BRUISING; STOMACH HEMORRHAGE; STOMACH ULCER; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT PLANNING; VASCULITIS; VOMITING; WEIGHT GAIN;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; GOUT; HUMANS; HYPERURICEMIA; PREVALENCE; URIC ACID;

EID: 27944471411     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774913318     Document Type: Review

References (67)

1. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355-60.
2. Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002; 11: 475-82.
3. Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 2001; 38: 365-71.
4. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-90.
5. Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S, et al. Peroxides properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 2002; 22: 1402-8.
6. Rich MW. Uric acid: is it a risk factor for cardiovascular disease?. Am J Cardiol 2000; 85: 1018-21.
7. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2001; 19: 1855-60.
8. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-6.
9. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14: 281-6.
10. The Hypertension Detection and Follow-up Program Cooperative Research Group. Mortality findings for stepped-care and referred-care participants in the Hypertension Detection and Follow-up Program, stratified by other risk factors. Prev Med 1985; 14: 312-35.
11. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141: 637-44.
12. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992. JAMA 2000; 283: 2404-10.
13. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, et al. Serum uric acid and hypertension: the Olivetti Heart Study. J Hum Hypertens 1994; 8: 677-81.
14. Feng DI, RJ Johnson. Hyperuricemia in childhood primary hypertension. Hypertension 2003; 42: 47-52.
15. Kelley WN, et al. (5th edition). Textbook of Rheumatology. Philadelphia: WB Saunders Co. 1997; 1313-51.
16. Kim KY, Schumacher HR, Hunsche E, Wertheimer AI, Kong SX. A literature review of the epidemiology and treatment of acute gout. Clin Therapeut 2003; 25: 1593-617.
17. Pascual E. Gout update: from lab to the clinic and back. Curr Opin Rheumatol 2000; 12: 213-8.
18. Terkeltaub R. Gout and mechanisms of crystal-induced inflammation. Curr Opin Rheumatol 1993; 5: 510-6.
19. Chapman PT, Yarwood H, Harrison AA, Stocker JJ, Jamar F, Gundel RH, et al. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1997; 40: 955-65.
20. Terkeltaub R, Baird S, Sears P, Santiago R, Boisvert W. The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in the air pouch model of acute urate-crystal-induced gouty synovitis. Arthritis Rheum 1998; 41: 900-9.
21. Matsukawa A, Yoshimura T, Maeda T, Takahashi T, Ohkawara S, Yoshinaga M. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1 beta, interleukin-8 and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis. Lab Invest 1998; 78: 559-69.
22. Nishimura A, Akahoshi T, Takahashi M, Takagishi K, Itoman M, Kondo H, et al. Attenuation of monosodium urate crystal-induced arthritis in rabbits by a neutralizing antibody against interleukin-8. J Leukoc Biol 1997; 62: 444-9.
23. Nacken W, Roth J, Sorg C, Kerhoff C. S100A9/S100A8: Myeloid representatives of the S100 protein family as predominant players in innate immunity. Microc Res Tech 20034; 60: 569-80.
24. Ryckman C, McColl SR, Vandal K, de Medicis R, Lussier A, Poubelle PE, et al. Role of s100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum 2003; 48: 2310-20.
25. Manitz MP, Horst B, Seeliger S, Strey A, Skryabin BV, Gunzer M, et al. Loss of S100A9 (MRP14) results in reduced interleukin-8 induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 2003; 23: 1034-43.
26. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 2003; 170: 3233-42.
27. Liu R, Aupperle K, Terkeltaub R. Src family protein tyrosine kinase signaling mediates monosodium urate crystal-induced IL-8 expression by monocytic THP-1 cells. J Leukoc Biol 2001; 70: 961-8.
28. Lui-Bryan R, Liote F, Rose DM, Merz D, Terkeltaub R. Pyk2 and Src kinase signaling transducer monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase-3, expression in chondrocytes. Arthritis Rheum 2004; in press.
29. Pouliot M, James MJ, Mccoll SR, Naccache PH, Cleleand LG. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998; 91: 1769-76.
30. Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkeltaub R. Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappa B transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum 2000; 43: 1145-55.
31. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-21.
32. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002; 109: 41-50.
33. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2002; 2: 787-95.
34. Landis RC, Yagnik DR, Florey O, Philippidis P, Emons V, Mason JC, et al. Safe disposal of inflammatory monosodium urate monohydrate crystals by differentiated macrophages. Arthritis Rheum 2002; 46: 3026-33.
35. Glass CK. Potential roles of the Peroxisome proliferators-activated receptor-gamma in macrophage biology and atherosclerosis. J Endocrinol 2001; 169: 461-4.
36. Akahoshi T, Namai R, Murakami Y, Watanabe M, Matsui T, Nishimura A, et al. Rapid induction of Peroxisome proliferators-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. Arthritis Rheum 2003; 48: 231-9.
37. Gilroy DW, Colville-Nash PR, McMaster S, Sawatzky DA, Willoughby DA, Lawrence T. Inducible cyclooxygenase-derived 15-deoxy(Delta)12-14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J 2003; 17: 2269-71.
38. Getting SJ, Christian HC, Flower RJ, Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002; 46: 2765-75.
39. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995; 96: 994-1002.
40. Chapman PT, Jamar F, Harrison AA, Schofield JB, Peters AM, Binns RM, et al. Characterization of E-selection expression, leukocyte traffic and clinical sequelae in urate crystal-induced inflammation: an insight into gout. Br J Rheumatol 1996; 35: 323-34.
41. Rott KT, Agudelo CA. Gout. JAMA 2003; 289: 2857-60.
42. Agudelo CA, Wise CM. Crystal-associated arthritis in the elderly. Rheum Clin N Am 2000; 26: 527-46.
43. Fam AG. Gout in the Elderly. Drugs Aging 1998; 13: 229-43.
44. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-103.
45. Choi RK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277-81.
46. Schlesinger N, Schumacher R. Gout: can management be improved? Curr Opin Rheumatol 2001; 13: 240-4.
47. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000; 43: 103-8.
48. Schumacher HR, Jr, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488-92.
49. Rubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50: 598-606.
50. Gonzalez E, Miller S, Agudelo C. Optimal management of gout in older patients. Drugs Aging 1994; 4: 128-34.
51. Terkeltaub R. Gout. N Engl J Med 2003; 349: 1647-55.
52. Noma S, Verho M, Iwane J, Yamaguda I, Osajima T, Kamezawa M, et al. Safety, tolerability, Pharmacokinetics, and lowering uric acid effect of repeated daily dosing with Y-700, a novel xanthine oxidase inhibitor in health male volunteers. Arthritis Rheum 2003; 48(9s): s530, abstract 1350.
53. Zhao L, Takano Y, Horiuchi H. Effect of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase (NP-SIXO), on enzymes in purine and pyrimidine metabolism. Arthritis Rheum 2003; 48(9s): s531, abstract 1352.
54. Arai M, Yokosuka O, Fujiwara K, Kojima H, Kanda T, Hirasawa H, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 2002; 17: 625-6.
55. Owens P, Kelly L, Nallen R, Ryan D, Fitzgerald D, O'Brien E. Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide - a randomized controlled trial. J Hypertens 2000; 18: 339-45.
56. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Re R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999; 17: 1033-9.
57. Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, et al.; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21: 4402-6.
58. Bessmertny O, Robitaille LM, Cairo MS. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr Pharm Design 2005; 11(32): 4177-4185.
59. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19: 697-704.
60. Bomalaski J, Goddard D, Grezlak D, Lopatin M, Holtzberg F, Ensor C, et al. Phase I study of uricase formulated with polyethylene glycol (uricase-PEG 20) Arthritis Rheum 2002; 46(9s): s141, abstract 287.
61. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, et al. Rosiglitazone, a ligand of the Peroxisome proliferators-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 2004; 483: 79-93.
62. Schachter M. Uric acid, hypertension and dyslipidaemia. Curr Pharm Design 2005; 11(32): 4139-43.
63. Wannamethee SG. Serum uric acid and risk of coronary heart disease. Curr Pharm Design 2005; 11(32): 4125-32.
64. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Design 2005; 11(32): 4161-75.
65. Amati L, Cirimele D, Pugliese V, Covelli V, Resta F, Jirillo E. Nutrition and immunity: laboratory and clinical aspects. Curr Pharm Design 2003; 9(24): 1924-31.
66. Holy A. Phosphonomethoxyalkyl analogs of nucleotides. Curr Pharm Design 2003; 9(31): 2567-92.
67. Sato Y. Modulation of PMN-endothelial cells interactions by cyclic nucleotides. Curr Pharm Design 2004; 10(2): 163-70.